High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Catherine Thiéblemont et al.|Blood|2015Cited by 157